Novo launches Saxenda in the U.S.

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) announced the U.S. launch of weight loss drug Saxenda liraglutide. Novo spokesperson Ken Inchausti said the drug's list price is $1,068/month.

FDA approved Saxenda in December for chronic weight management as an adjunct to diet and exercise in adults with a BMI of at least 30 or a BMI of at least 27 and at least one co-morbidity. Novo also markets lower doses of long-acting liraglutide as Victoza for Type II diabetes (see BioCentury Extra, Dec. 23, 2014). ...